Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

1M ago

PBM

PremiumPress Releases

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

1M ago

PBM

PremiumPress Releases

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

2M ago

PBM

PremiumPress Releases

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

2M ago

PBM

PremiumPress Releases

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

2M ago

PBM

PremiumPress Releases

Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

2M ago

PBM

More PBM News >

PBM News on the Web

2024-05-17

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

Yahoo Finance

Neutral

2024-04-17

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry

Yahoo Finance

Neutral

2024-04-16

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Yahoo Finance

Neutral

2024-04-08

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Yahoo Finance

Neutral

2024-03-26

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

Yahoo Finance

Neutral

2024-03-18

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

Yahoo Finance

Neutral

2024-03-15

Psyence Biomedical faces Nasdaq delisting over market value

Investing.com

Neutral

2024-03-15

Psyence Biomedical faces Nasdaq delisting over market value

Investing.com

Neutral

News Score - Last 7 Days

Neutral

PBM

Sector Average

Media Buzz

This Week1 articles

Weekly Average1 articles

News Sentiment

This Week50%

Sector Average59%

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is PBM’s Media Buzz Sentiment?

1 articles about PBM were published this week. In an average week, 1 articles are published.

What is PBM’s weekly average amount of articles?

In an average week, 1 articles about PBM are published.

What is PBM’s News Sentiment?

50% of articles about PBM were positive this week, compared to its sector average of 59%.

Financial Stocks that are Trending in the News

CBChubb

MUFGMitsubishi UFJ

IBTXIndependent Bank Group

CTBICommunity Bancorp

ZFSVFZurich Insurance Group

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing